We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
-0.04%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$310M
AUM Growth
-$3.76M
Cap. Flow
+$165M
Cap. Flow %
53.25%
Top 10 Hldgs %
45.45%
Holding
43
New
4
Increased
13
Reduced
15
Closed
4

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$53.2M
2
DXCM icon
DexCom
DXCM
+$37.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
JNJ icon
Johnson & Johnson
JNJ
+$21.5M
5
CAH icon
Cardinal Health
CAH
+$18.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$18.7M
2
CVS icon
CVS Health
CVS
+$6.37M
3
BSX icon
Boston Scientific
BSX
+$5.46M
4
UFPT icon
UFP Technologies
UFPT
+$5.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.06T
$26.8M 8.67%
39,722
+8,589
+28% +$8.71M
MRK icon
2
Merck
MRK
$317B
$22.9M 7.4%
33,853
-161,915
-83% -$18.7M
TMO icon
3
Thermo Fisher Scientific
TMO
$214B
$14.4M 4.67%
22,986
-6,929
-23% -$3.76M
ONC
4
BeOne Medicines Ltd
ONC
$36.7B
$12.1M 3.92%
41,717
+1,285
+3% +$416K
JNJ icon
5
Johnson & Johnson
JNJ
$619B
$11.9M 3.86%
+92,377
New +$21.5M
BBIO icon
6
BridgeBio Pharma
BBIO
$16.2B
$11.9M 3.84%
111,363
-29,933
-21% -$2.17M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$123B
$11.2M 3.61%
22,984
– –
ABBV icon
8
AbbVie
ABBV
$431B
$10.4M 3.35%
108,181
– –
SYK icon
9
Stryker
SYK
$129B
$9.58M 3.09%
26,835
– –
ISRG icon
10
Intuitive Surgical
ISRG
$132B
$9.44M 3.05%
70,851
+48,529
+217% +$24.6M
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.06B
$9.4M 3.03%
27,873
-64,504
-70% -$5.09M
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$5.74B
$9.4M 3.03%
195,768
+106,083
+118% +$9.98M
CVS icon
13
CVS Health
CVS
$123B
$9.27M 2.99%
23,773
-82,745
-78% -$6.37M
RVMD icon
14
Revolution Medicines
RVMD
$42.1B
$9.08M 2.93%
617,245
+527,061
+584% +$53.2M
BSX icon
15
Boston Scientific
BSX
$71.4B
$8.84M 2.86%
40,432
-68,250
-63% -$5.46M
AMGN icon
16
Amgen
AMGN
$219B
$8.72M 2.81%
21,903
– –
EW icon
17
Edwards Lifesciences
EW
$51.5B
$8.27M 2.67%
+106,518
New +$8.78M
ALKS icon
18
Alkermes
ALKS
$8.11B
$8.24M 2.66%
242,473
– –
INCY icon
19
Incyte
INCY
$24B
$7.97M 2.57%
50,796
-20,055
-28% -$2M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.2B
$7.85M 2.54%
89,685
-5,111
-5% -$678K
GILD icon
21
Gilead Sciences
GILD
$162B
$7.16M 2.31%
47,967
-2,829
-6% -$396K
KRYS icon
22
Krystal Biotech
KRYS
$9.55B
$6.79M 2.19%
37,579
+3,726
+11% +$991K
COR icon
23
Cencora
COR
$63.2B
$6.6M 2.13%
23,470
-303
-1% -$106K
IRTC icon
24
iRhythm Holdings
IRTC
$4.21B
$6.26M 2.02%
22,322
-15,257
-41% -$2.2M
INSM icon
25
Insmed
INSM
$28.7B
$5.96M 1.92%
97,438
+69,565
+250% +$10.7M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q1 2026 Portfolio in Review

As of Q1 2026, HealthInvest Partners held 43 positions worth $310M, down 1.2% from $313M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

HealthInvest Partners deployed $165M of net new capital in Q1 2026, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Johnson & Johnson: 92,377 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merck, an estimated $18.7M trimmed.

  • HealthInvest Partners's largest Q1 2026 buy was Johnson & Johnson: 92,377 shares worth $11.9M.
  • HealthInvest Partners added most to Revolution Medicines in Q1 2026, an estimated $53.2M increase.
  • HealthInvest Partners's biggest Q1 2026 reduction was Merck, cutting an estimated $18.7M.
  • HealthInvest Partners fully exited UFP Technologies in Q1 2026, selling an estimated $5.1M.
  • HealthInvest Partners's ten largest holdings make up 45% of its $310M portfolio in Q1 2026.
  • HealthInvest Partners opened 4 new positions and closed 4 in Q1 2026.
  • HealthInvest Partners's portfolio value fell 1.2% quarter-over-quarter to $310M.

Based on HealthInvest Partners's 13F filing for Q1 2026, filed 11 May 2026.